title: Does tadalafil prevent erectile dysfunction in patients undergoing radiation therapy for prostate cancer?
abstract: A recently published paper addressed the interesting topic of prevention of erectile dysfunction (ED) with tadalafil, a phosphodiesterase-type 5 inhibitor (PDE5i) in patients undergoing radiation therapy for localized prostate cancer. Tadalafil 5 mg or placebo was administered once-daily for 24 weeks in patients undergoing external-beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer. This randomized trial did not show superior efficacy of the active drug compared with placebo 4-6 weeks after stopping the study drug. Furthermore, patients younger than 65 years did not respond significantly better than older patients.
authors: Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, 3000 CA, The Netherlands.
authors: Luca
authors: L
authors: Incrocci
mesh_terms: D002243:Carbolines / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000517:prevention & control*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000517:prevention & control*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D002243:Carbolines; D014665:Vasodilator Agents